



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/14

Date: 15th May 2026

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Approval of upto U.S. \$ 20,000,000 of 8.00% Senior Unsecured Foreign Currency Convertible Bonds due 2029 of Sudarshan Pharma Industries Limited

In continuation to our earlier communication dated May 12, 2026, and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that pursuant to the approval of the members of the Company dated August 11, 2025, for the proposed issuance of foreign currency convertible bonds, and based on the In-principle approvals granted by BSE Limited dated September 25, 2025, the Board of Directors of the Company, at its meeting held on May 15, 2026, has, inter alia, considered and approved the following:

- (i) Issuance of upto U.S. \$ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches, of Sudarshan Pharma Industries Limited ("FCCBs");
- (ii) approved the draft Offering Circular dated on or about May 15, 2026;
- (iii) Opening of the issuance of FCCBs on May 18, 2026;
- (iv) approved the 'Relevant Date' for the purpose of the Issue of FCCBs as May 15, 2026 in accordance with the Issue of Foreign Currency Convertible Bonds and Ordinary Shares (Through Depository Receipt Mechanism) Scheme, 1993, as amended ("FCCBs Guidelines") and accordingly, the regulatory floor price as determined in accordance with the FCCBs Guidelines is Rs.30.19;
- (v) Mr. Hemal Vasantrai Mehta, Chairman & Managing Director and / or Mr. Sachin Vasantrai Mehta, Joint Managing Director have been duly authorised to sign all the documents related to the issue of FCCBs including agreements, powers of attorney, undertaking and indemnities, if necessary and make any amendments to the documents before or after execution and to take any and all decisions in respect to issuance of the FCCBs.

The details required to be disclosed as per Regulation 30 of SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure – A.

For Sudarshan Pharma Industries Limited


Sachin Mehta
Joint Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

Annexure – A

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| Sr. No. | Particulars | Details |
|---------|---|--|
| a) | Type of securities proposed to be issued | Foreign Currency Convertible Bonds (FCCBs) |
| b) | Type of issuance | International offering |
| c) | Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately) | Upto USD 20 million in one or more tranches |
| d) | In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s) | Not Applicable |
| e) | In case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s) | Not Applicable |
| f) | In case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s) | |
| i) | Name of the stock exchange(s) where ADR/GDR/FCCBs are listed (opening – closing status) / proposed to be listed: | -- |
| ii) | Proposed no. of equity shares underlying the ADR/GDR or on conversion of FCCBs; | Considering Issue Size of up to USD 20 million equivalent to INR 191.86 Crores, the number of equity shares on conversion would be approximately 6,35,50,845 equity shares of Re.1/- each of the Company calculated on the basis of Floor Price. |
| iii) | a) proposed date of allotment; b) tenure, date of maturity; and c) coupon offered, if any of FCCB's | a) FCCBs will be allotted within 60 days from the Issue Closing Date. b) 3 years and 2 months from the date of the FCCBs being fully paid-up. c) 8% per annum |





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

| Sr. No. | Particulars | Details |
|---------|--|---|
| iv) | Issue price of ADR/GDR/FCCBs (in terms of USD and in INR after considering conversion rate): | Issuance of FCCBs up to USD 20 million After considering conversion rate of USD 1 = Rs.95.93, it would amount to Rs. 191.86 Crores |
| v) | change in terms of FCCBs, if any: | Not Applicable |
| vi) | details of defaults, if any, by the listed entity in payment of coupon on FCCBs & subsequent updates in relation to the default, including the details of the corrective measures undertaken (if any): | Nil |
| g) | In case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s) | Not Applicable |
| h) | Any cancellation or termination of proposal for issuance of securities including reasons thereof. | Not Applicable |

For Sudarshan Pharma Industries Limited


Sachin Mehta
Joint Managing Director

